Global In-Silico Drug Discovery Market Research Report 2026

In-Silico Drug Discovery Market

In-silico drug discovery is an R&D approach centered on computational chemistry, molecular simulation, and machine learning to virtually screen, design, and optimize targets and candidate molecules, with the aim of narrowing chemical space, improving hit rates, and surfacing developability risks before wet-lab work. Typical capabilities include structure-informed design and virtual screening, such as molecular docking, pharmacophore and similarity search, molecular dynamics, and free energy calculations, to evaluate binding modes, selectivity, and structure-activity relationships, combined with QSAR (quantitative structure–activity relationship) and multi-parameter models to predict physicochemical properties, potency, and ADMET (absorption, distribution, metabolism, excretion, and toxicity) and toxicity outcomes for lead optimization and prioritization. With the adoption of generative models and automated workflows, platforms can propose synthetically feasible molecular modifications and suggest synthetic routes, while consolidating chemistry and biology data within a unified, collaborative informatics system to enable a design–make–test–analyze (DMTA) decision loop. Use cases primarily serve pharma and biotech companies as well as CROs across early discovery and preclinical stages, spanning hit identification, hit-to-lead, lead optimization, and candidate nomination; some vendors further extend into digital twins and clinical trial simulation built on human data and disease models to support development decisions such as dose regimen and inclusion/exclusion criteria. Delivery models include software suites and cloud SaaS subscriptions, enterprise on-premises deployments, and milestone-based joint R&D and outsourced services. At the tooling layer, offerings range from integrated environments for molecular modeling and property calculation, to R&D informatics platforms for project and data governance, and simulation tools for population PK/PD and PBPK (physiologically based pharmacokinetic) modeling, all aimed at improving go/no-go decisions at key milestones and enhancing cross-team collaboration efficiency.

In-silico drug discovery is evolving from a set of fragmented computational chemistry tools into a system-level R&D methodology that spans hit identification through lead optimization and is increasingly embedded in a design–make–test–analyze (DMTA) decision loop. At its core, it narrows chemical space before wet-lab work by using structural information and historical data to prioritize candidates that are more likely to be both active and developable. A typical workflow combines structure-based virtual screening and molecular design, including protein structure preparation, binding-pocket identification, molecular docking and scoring, pharmacophore and similarity search, fragment linking and growing, as well as molecular dynamics and free energy calculations to validate binding modes and selectivity. In parallel, data-driven models support multi-objective trade-offs through QSAR (quantitative structure–activity relationship) and multi-parameter optimization to predict physicochemical properties and exposure-related risks, surfacing potential issues in solubility, permeability, metabolic stability, and safety earlier. This reduces blind synthesis and repetitive experiments, concentrates lab resources on higher-confidence directions, and establishes an interpretable prioritization logic for candidate selection in the early stages.

Competitive differentiation is shifting from standalone model accuracy toward data assets, engineering-grade delivery, and scalable workflows. High-quality training data and robust negative example coverage define the limits of model generalization, while the data loop between computation and experiments determines iteration speed. As a result, collaborative R&D informatics platforms have become a critical, often “invisible,” layer of infrastructure: they integrate multi-source data across chemistry, biology, DMPK, and preclinical functions; enable version control, access governance, and traceable audit trails; and support consistent prioritization and project governance across teams. Meanwhile, cloud-native delivery and HPC scheduling package compute, models, and automated pipelines into deployable offerings, lowering operational barriers through browser-based experiences and standardized APIs. Workflow orchestration further connects docking, simulation, property prediction, and synthetic feasibility assessment within a single workbench. Generative models and automated workflows are also bringing routine capabilities for proposing molecular modifications and suggesting synthetic routes, making design outputs more aligned with synthetic accessibility and manufacturability. Ultimately, the value is not only in finding hits faster, but in shifting uncertainty earlier in the process, extracting higher information density from fewer experiments, and improving the quality of go/no-go decisions at key milestones.

Commercialization commonly spans software subscriptions, enterprise on-premises deployments, and milestone-based joint R&D projects, with customers evaluating ROI through measurable outcomes such as higher hit rates, shorter timelines, lower attrition, and reduced experimental spend. On the supply side, “production” and delivery are increasingly organized through a global multi-hub division of labor. Platform and software vendors often place product management, customer success, and solution architecture in North America and Europe to stay close to large pharma demand and compliance requirements, while building R&D engineering and algorithm support capacity in India and East Asia to leverage talent pools and cost advantages, enabled by cloud-based cross-region delivery. Service-oriented CROs and CRDMOs, by contrast, rely on multi-country laboratory and project management footprints to integrate computational design with synthesis, screening, and DMPK validation into end-to-end delivery, supporting both outsourcing and co-development. On the demand side, sales coverage typically centers on North America, Europe, and Asia–Pacific, with local teams clustered around major innovation and pharma hubs such as Boston, the San Francisco Bay Area, London, Basel, Singapore, and Shanghai. Vendors emphasize follow-the-sun collaboration and localized support to expand subscription renewals and deepen project partnerships, while codifying successful cases into transferable playbooks that can be replicated at scale.

This report delivers a comprehensive overview of the global In-Silico Drug Discovery market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding In-Silico Drug Discovery. The In-Silico Drug Discovery market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global In-Silico Drug Discovery market comprehensively. Regional market sizes by Type, by Application, by Method Paradigm, and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist In-Silico Drug Discovery manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of In-Silico Drug Discovery Market Report

Chapter Outline

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global In-Silico Drug Discovery Market Size Growth Rate by Type: 2021 vs 2025 vs 2032

1.2.2 Software as a Service (Cloud)

1.2.3 Consultancy as a Service

1.2.4 Software

1.3 Market by Method Paradigm

1.3.1 Global In-Silico Drug Discovery Market Size Growth Rate by Method Paradigm: 2021 vs 2025 vs 2032

1.3.2 Physics and Structure-based

1.3.3 Data-driven

1.3.4 Hybrid

1.4 Market by Modality

1.4.1 Global In-Silico Drug Discovery Market Size Growth Rate by Modality: 2021 vs 2025 vs 2032

1.4.2 Small Molecule-first

1.4.3 Biologics/Antibody-focused

1.4.4 Multi-modality

1.5 Market by Application

1.5.1 Global In-Silico Drug Discovery Market Growth by Application: 2021 vs 2025 vs 2032

1.5.2 Contract Research Organization

1.5.3 Pharmaceutical Industry

1.5.4 Academic and Research Institutes

1.5.5 Others

1.6 Assumptions and Limitations

1.7 Study Objectives

1.8 Years Considered

2.1 Global In-Silico Drug Discovery Market Perspective (2021–2032)

2.2 Global In-Silico Drug Discovery Growth Trends by Region

2.2.1 Global In-Silico Drug Discovery Market Size by Region: 2021 vs 2025 vs 2032

2.2.2 In-Silico Drug Discovery Historic Market Size by Region (2021–2026)

2.2.3 In-Silico Drug Discovery Forecasted Market Size by Region (2027–2032)

2.3 In-Silico Drug Discovery Market Dynamics

2.3.1 In-Silico Drug Discovery Industry Trends

2.3.2 In-Silico Drug Discovery Market Drivers

2.3.3 In-Silico Drug Discovery Market Challenges

2.3.4 In-Silico Drug Discovery Market Restraints

3.1 Global Top In-Silico Drug Discovery Players by Revenue

3.1.1 Global Top In-Silico Drug Discovery Players by Revenue (2021–2026)

3.1.2 Global In-Silico Drug Discovery Revenue Market Share by Players (2021–2026)

3.2 Global Top In-Silico Drug Discovery Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

3.3 Global Key Players Ranking by In-Silico Drug Discovery Revenue

3.4 Global In-Silico Drug Discovery Market Concentration Ratio

3.4.1 Global In-Silico Drug Discovery Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by In-Silico Drug Discovery Revenue in 2025

3.5 Global Key Players of In-Silico Drug Discovery Head Offices and Areas Served

3.6 Global Key Players of In-Silico Drug Discovery, Products and Applications

3.7 Global Key Players of In-Silico Drug Discovery, Date of General Availability (GA)

3.8 Mergers and Acquisitions, Expansion Plans

4.1 Global In-Silico Drug Discovery Historic Market Size by Type (2021–2026)

4.2 Global In-Silico Drug Discovery Forecasted Market Size by Type (2027–2032)

5.1 Global In-Silico Drug Discovery Historic Market Size by Application (2021–2026)

5.2 Global In-Silico Drug Discovery Forecasted Market Size by Application (2027–2032)

6.1 North America In-Silico Drug Discovery Market Size (2021–2032)

6.2 North America In-Silico Drug Discovery Market Growth Rate by Country: 2021 vs 2025 vs 2032

6.3 North America In-Silico Drug Discovery Market Size by Country (2021–2026)

6.4 North America In-Silico Drug Discovery Market Size by Country (2027–2032)

6.5 United States

6.6 Canada

7.1 Europe In-Silico Drug Discovery Market Size (2021–2032)

7.2 Europe In-Silico Drug Discovery Market Growth Rate by Country: 2021 vs 2025 vs 2032

7.3 Europe In-Silico Drug Discovery Market Size by Country (2021–2026)

7.4 Europe In-Silico Drug Discovery Market Size by Country (2027–2032)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8.1 Asia-Pacific In-Silico Drug Discovery Market Size (2021–2032)

8.2 Asia-Pacific In-Silico Drug Discovery Market Growth Rate by Region: 2021 vs 2025 vs 2032

8.3 Asia-Pacific In-Silico Drug Discovery Market Size by Region (2021–2026)

8.4 Asia-Pacific In-Silico Drug Discovery Market Size by Region (2027–2032)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9.1 Latin America In-Silico Drug Discovery Market Size (2021–2032)

9.2 Latin America In-Silico Drug Discovery Market Growth Rate by Country: 2021 vs 2025 vs 2032

9.3 Latin America In-Silico Drug Discovery Market Size by Country (2021–2026)

9.4 Latin America In-Silico Drug Discovery Market Size by Country (2027–2032)

9.5 Mexico

9.6 Brazil

10.1 Middle East & Africa In-Silico Drug Discovery Market Size (2021–2032)

10.2 Middle East & Africa In-Silico Drug Discovery Market Growth Rate by Country: 2021 vs 2025 vs 2032

10.3 Middle East & Africa In-Silico Drug Discovery Market Size by Country (2021–2026)

10.4 Middle East & Africa In-Silico Drug Discovery Market Size by Country (2027–2032)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11.1 Allucent (formerly Nuventra)

11.1.1 Allucent (formerly Nuventra) Company Details

11.1.2 Allucent (formerly Nuventra) Business Overview

11.1.3 Allucent (formerly Nuventra) In-Silico Drug Discovery Introduction

11.1.4 Allucent (formerly Nuventra) Revenue in In-Silico Drug Discovery Business (2021–2026)

11.1.5 Allucent (formerly Nuventra) Recent Development

11.2 Jubilant Biosys

11.2.1 Jubilant Biosys Company Details

11.2.2 Jubilant Biosys Business Overview

11.2.3 Jubilant Biosys In-Silico Drug Discovery Introduction

11.2.4 Jubilant Biosys Revenue in In-Silico Drug Discovery Business (2021–2026)

11.2.5 Jubilant Biosys Recent Development

11.3 Shanghai ChemPartner Co., Ltd

11.3.1 Shanghai ChemPartner Co., Ltd Company Details

11.3.2 Shanghai ChemPartner Co., Ltd Business Overview

11.3.3 Shanghai ChemPartner Co., Ltd In-Silico Drug Discovery Introduction

11.3.4 Shanghai ChemPartner Co., Ltd Revenue in In-Silico Drug Discovery Business (2021–2026)

11.3.5 Shanghai ChemPartner Co., Ltd Recent Development

11.4 Shanghai Medicilon Inc.

11.4.1 Shanghai Medicilon Inc. Company Details

11.4.2 Shanghai Medicilon Inc. Business Overview

11.4.3 Shanghai Medicilon Inc. In-Silico Drug Discovery Introduction

11.4.4 Shanghai Medicilon Inc. Revenue in In-Silico Drug Discovery Business (2021–2026)

11.4.5 Shanghai Medicilon Inc. Recent Development

11.5 Pharmaron

11.5.1 Pharmaron Company Details

11.5.2 Pharmaron Business Overview

11.5.3 Pharmaron In-Silico Drug Discovery Introduction

11.5.4 Pharmaron Revenue in In-Silico Drug Discovery Business (2021–2026)

11.5.5 Pharmaron Recent Development

11.6 BioDuro-Sundia

11.6.1 BioDuro-Sundia Company Details

11.6.2 BioDuro-Sundia Business Overview

11.6.3 BioDuro-Sundia In-Silico Drug Discovery Introduction

11.6.4 BioDuro-Sundia Revenue in In-Silico Drug Discovery Business (2021–2026)

11.6.5 BioDuro-Sundia Recent Development

11.7 Syngene

11.7.1 Syngene Company Details

11.7.2 Syngene Business Overview

11.7.3 Syngene In-Silico Drug Discovery Introduction

11.7.4 Syngene Revenue in In-Silico Drug Discovery Business (2021–2026)

11.7.5 Syngene Recent Development

11.8 TCG Lifesciences Private Limited

11.8.1 TCG Lifesciences Private Limited Company Details

11.8.2 TCG Lifesciences Private Limited Business Overview

11.8.3 TCG Lifesciences Private Limited In-Silico Drug Discovery Introduction

11.8.4 TCG Lifesciences Private Limited Revenue in In-Silico Drug Discovery Business (2021–2026)

11.8.5 TCG Lifesciences Private Limited Recent Development

11.9 Viva Biotech (Shanghai) Ltd

11.9.1 Viva Biotech (Shanghai) Ltd Company Details

11.9.2 Viva Biotech (Shanghai) Ltd Business Overview

11.9.3 Viva Biotech (Shanghai) Ltd In-Silico Drug Discovery Introduction

11.9.4 Viva Biotech (Shanghai) Ltd Revenue in In-Silico Drug Discovery Business (2021–2026)

11.9.5 Viva Biotech (Shanghai) Ltd Recent Development

11.10 Profacgen

11.10.1 Profacgen Company Details

11.10.2 Profacgen Business Overview

11.10.3 Profacgen In-Silico Drug Discovery Introduction

11.10.4 Profacgen Revenue in In-Silico Drug Discovery Business (2021–2026)

11.10.5 Profacgen Recent Development

11.11 Creative BioLabs

11.11.1 Creative BioLabs Company Details

11.11.2 Creative BioLabs Business Overview

11.11.3 Creative BioLabs In-Silico Drug Discovery Introduction

11.11.4 Creative BioLabs Revenue in In-Silico Drug Discovery Business (2021–2026)

11.11.5 Creative BioLabs Recent Development

11.12 Aitia (formerly GNS Healthcare)

11.12.1 Aitia (formerly GNS Healthcare) Company Details

11.12.2 Aitia (formerly GNS Healthcare) Business Overview

11.12.3 Aitia (formerly GNS Healthcare) In-Silico Drug Discovery Introduction

11.12.4 Aitia (formerly GNS Healthcare) Revenue in In-Silico Drug Discovery Business (2021–2026)

11.12.5 Aitia (formerly GNS Healthcare) Recent Development

11.13 Novadiscovery

11.13.1 Novadiscovery Company Details

11.13.2 Novadiscovery Business Overview

11.13.3 Novadiscovery In-Silico Drug Discovery Introduction

11.13.4 Novadiscovery Revenue in In-Silico Drug Discovery Business (2021–2026)

11.13.5 Novadiscovery Recent Development

11.14 Recursion Pharmaceuticals

11.14.1 Recursion Pharmaceuticals Company Details

11.14.2 Recursion Pharmaceuticals Business Overview

11.14.3 Recursion Pharmaceuticals In-Silico Drug Discovery Introduction

11.14.4 Recursion Pharmaceuticals Revenue in In-Silico Drug Discovery Business (2021–2026)

11.14.5 Recursion Pharmaceuticals Recent Development

11.15 insitro

11.15.1 insitro Company Details

11.15.2 insitro Business Overview

11.15.3 insitro In-Silico Drug Discovery Introduction

11.15.4 insitro Revenue in In-Silico Drug Discovery Business (2021–2026)

11.15.5 insitro Recent Development

11.16 Numerion Labs (formerly Atomwise)

11.16.1 Numerion Labs (formerly Atomwise) Company Details

11.16.2 Numerion Labs (formerly Atomwise) Business Overview

11.16.3 Numerion Labs (formerly Atomwise) In-Silico Drug Discovery Introduction

11.16.4 Numerion Labs (formerly Atomwise) Revenue in In-Silico Drug Discovery Business (2021–2026)

11.16.5 Numerion Labs (formerly Atomwise) Recent Development

11.17 BenevolentAI

11.17.1 BenevolentAI Company Details

11.17.2 BenevolentAI Business Overview

11.17.3 BenevolentAI In-Silico Drug Discovery Introduction

11.17.4 BenevolentAI Revenue in In-Silico Drug Discovery Business (2021–2026)

11.17.5 BenevolentAI Recent Development

11.18 XtalPi

11.18.1 XtalPi Company Details

11.18.2 XtalPi Business Overview

11.18.3 XtalPi In-Silico Drug Discovery Introduction

11.18.4 XtalPi Revenue in In-Silico Drug Discovery Business (2021–2026)

11.18.5 XtalPi Recent Development

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

List of Tables

 Table 1. Global In-Silico Drug Discovery Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032

 Table 2. Key Players of Software as a Service (Cloud)

 Table 3. Key Players of Consultancy as a Service

 Table 4. Key Players of Software

 Table 5. Global In-Silico Drug Discovery Market Size Growth Rate by Method Paradigm (US$ Million): 2021 vs 2025 vs 2032

 Table 6. Key Players of Physics and Structure-based

 Table 7. Key Players of Data-driven

 Table 8. Key Players of Hybrid

 Table 9. Global In-Silico Drug Discovery Market Size Growth Rate by Modality (US$ Million): 2021 vs 2025 vs 2032

 Table 10. Key Players of Small Molecule-first

 Table 11. Key Players of Biologics/Antibody-focused

 Table 12. Key Players of Multi-modality

 Table 13. Global In-Silico Drug Discovery Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032

 Table 14. Global In-Silico Drug Discovery Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

 Table 15. Global In-Silico Drug Discovery Market Size by Region (US$ Million), 2021–2026

 Table 16. Global In-Silico Drug Discovery Market Share by Region (2021–2026)

 Table 17. Global In-Silico Drug Discovery Forecasted Market Size by Region (US$ Million), 2027–2032

 Table 18. Global In-Silico Drug Discovery Market Share by Region (2027–2032)

 Table 19. In-Silico Drug Discovery Market Trends

 Table 20. In-Silico Drug Discovery Market Drivers

 Table 21. In-Silico Drug Discovery Market Challenges

 Table 22. In-Silico Drug Discovery Market Restraints

 Table 23. Global In-Silico Drug Discovery Revenue by Players (US$ Million), 2021–2026

 Table 24. Global In-Silico Drug Discovery Market Share by Players (2021–2026)

 Table 25. Global Top In-Silico Drug Discovery Players by Tier (Tier 1, Tier 2, and Tier 3), based on In-Silico Drug Discovery Revenue, 2025

 Table 26. Ranking of Global Top In-Silico Drug Discovery Companies by Revenue (US$ Million) in 2025

 Table 27. Global 5 Largest Players Market Share by In-Silico Drug Discovery Revenue (CR5 and HHI), 2021–2026

 Table 28. Global Key Players of In-Silico Drug Discovery, Headquarters and Area Served

 Table 29. Global Key Players of In-Silico Drug Discovery, Products and Applications

 Table 30. Global Key Players of In-Silico Drug Discovery, Date of General Availability (GA)

 Table 31. Mergers and Acquisitions, Expansion Plans

 Table 32. Global In-Silico Drug Discovery Market Size by Type (US$ Million), 2021–2026

 Table 33. Global In-Silico Drug Discovery Revenue Market Share by Type (2021–2026)

 Table 34. Global In-Silico Drug Discovery Forecasted Market Size by Type (US$ Million), 2027–2032

 Table 35. Global In-Silico Drug Discovery Revenue Market Share by Type (2027–2032)

 Table 36. Global In-Silico Drug Discovery Market Size by Application (US$ Million), 2021–2026

 Table 37. Global In-Silico Drug Discovery Revenue Market Share by Application (2021–2026)

 Table 38. Global In-Silico Drug Discovery Forecasted Market Size by Application (US$ Million), 2027–2032

 Table 39. Global In-Silico Drug Discovery Revenue Market Share by Application (2027–2032)

 Table 40. North America In-Silico Drug Discovery Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

 Table 41. North America In-Silico Drug Discovery Market Size by Country (US$ Million), 2021–2026

 Table 42. North America In-Silico Drug Discovery Market Size by Country (US$ Million), 2027–2032

 Table 43. Europe In-Silico Drug Discovery Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

 Table 44. Europe In-Silico Drug Discovery Market Size by Country (US$ Million), 2021–2026

 Table 45. Europe In-Silico Drug Discovery Market Size by Country (US$ Million), 2027–2032

 Table 46. Asia-Pacific In-Silico Drug Discovery Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032

 Table 47. Asia-Pacific In-Silico Drug Discovery Market Size by Region (US$ Million), 2021–2026

 Table 48. Asia-Pacific In-Silico Drug Discovery Market Size by Region (US$ Million), 2027–2032

 Table 49. Latin America In-Silico Drug Discovery Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

 Table 50. Latin America In-Silico Drug Discovery Market Size by Country (US$ Million), 2021–2026

 Table 51. Latin America In-Silico Drug Discovery Market Size by Country (US$ Million), 2027–2032

 Table 52. Middle East & Africa In-Silico Drug Discovery Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

 Table 53. Middle East & Africa In-Silico Drug Discovery Market Size by Country (US$ Million), 2021–2026

 Table 54. Middle East & Africa In-Silico Drug Discovery Market Size by Country (US$ Million), 2027–2032

 Table 55. Allucent (formerly Nuventra) Company Details

 Table 56. Allucent (formerly Nuventra) Business Overview

 Table 57. Allucent (formerly Nuventra) In-Silico Drug Discovery Product

 Table 58. Allucent (formerly Nuventra) Revenue in In-Silico Drug Discovery Business (US$ Million), 2021–2026

 Table 59. Allucent (formerly Nuventra) Recent Development

 Table 60. Jubilant Biosys Company Details

 Table 61. Jubilant Biosys Business Overview

 Table 62. Jubilant Biosys In-Silico Drug Discovery Product

 Table 63. Jubilant Biosys Revenue in In-Silico Drug Discovery Business (US$ Million), 2021–2026

 Table 64. Jubilant Biosys Recent Development

 Table 65. Shanghai ChemPartner Co., Ltd Company Details

 Table 66. Shanghai ChemPartner Co., Ltd Business Overview

 Table 67. Shanghai ChemPartner Co., Ltd In-Silico Drug Discovery Product

 Table 68. Shanghai ChemPartner Co., Ltd Revenue in In-Silico Drug Discovery Business (US$ Million), 2021–2026

 Table 69. Shanghai ChemPartner Co., Ltd Recent Development

 Table 70. Shanghai Medicilon Inc. Company Details

 Table 71. Shanghai Medicilon Inc. Business Overview

 Table 72. Shanghai Medicilon Inc. In-Silico Drug Discovery Product

 Table 73. Shanghai Medicilon Inc. Revenue in In-Silico Drug Discovery Business (US$ Million), 2021–2026

 Table 74. Shanghai Medicilon Inc. Recent Development

 Table 75. Pharmaron Company Details

 Table 76. Pharmaron Business Overview

 Table 77. Pharmaron In-Silico Drug Discovery Product

 Table 78. Pharmaron Revenue in In-Silico Drug Discovery Business (US$ Million), 2021–2026

 Table 79. Pharmaron Recent Development

 Table 80. BioDuro-Sundia Company Details

 Table 81. BioDuro-Sundia Business Overview

 Table 82. BioDuro-Sundia In-Silico Drug Discovery Product

 Table 83. BioDuro-Sundia Revenue in In-Silico Drug Discovery Business (US$ Million), 2021–2026

 Table 84. BioDuro-Sundia Recent Development

 Table 85. Syngene Company Details

 Table 86. Syngene Business Overview

 Table 87. Syngene In-Silico Drug Discovery Product

 Table 88. Syngene Revenue in In-Silico Drug Discovery Business (US$ Million), 2021–2026

 Table 89. Syngene Recent Development

 Table 90. TCG Lifesciences Private Limited Company Details

 Table 91. TCG Lifesciences Private Limited Business Overview

 Table 92. TCG Lifesciences Private Limited In-Silico Drug Discovery Product

 Table 93. TCG Lifesciences Private Limited Revenue in In-Silico Drug Discovery Business (US$ Million), 2021–2026

 Table 94. TCG Lifesciences Private Limited Recent Development

 Table 95. Viva Biotech (Shanghai) Ltd Company Details

 Table 96. Viva Biotech (Shanghai) Ltd Business Overview

 Table 97. Viva Biotech (Shanghai) Ltd In-Silico Drug Discovery Product

 Table 98. Viva Biotech (Shanghai) Ltd Revenue in In-Silico Drug Discovery Business (US$ Million), 2021–2026

 Table 99. Viva Biotech (Shanghai) Ltd Recent Development

 Table 100. Profacgen Company Details

 Table 101. Profacgen Business Overview

 Table 102. Profacgen In-Silico Drug Discovery Product

 Table 103. Profacgen Revenue in In-Silico Drug Discovery Business (US$ Million), 2021–2026

 Table 104. Profacgen Recent Development

 Table 105. Creative BioLabs Company Details

 Table 106. Creative BioLabs Business Overview

 Table 107. Creative BioLabs In-Silico Drug Discovery Product

 Table 108. Creative BioLabs Revenue in In-Silico Drug Discovery Business (US$ Million), 2021–2026

 Table 109. Creative BioLabs Recent Development

 Table 110. Aitia (formerly GNS Healthcare) Company Details

 Table 111. Aitia (formerly GNS Healthcare) Business Overview

 Table 112. Aitia (formerly GNS Healthcare) In-Silico Drug Discovery Product

 Table 113. Aitia (formerly GNS Healthcare) Revenue in In-Silico Drug Discovery Business (US$ Million), 2021–2026

 Table 114. Aitia (formerly GNS Healthcare) Recent Development

 Table 115. Novadiscovery Company Details

 Table 116. Novadiscovery Business Overview

 Table 117. Novadiscovery In-Silico Drug Discovery Product

 Table 118. Novadiscovery Revenue in In-Silico Drug Discovery Business (US$ Million), 2021–2026

 Table 119. Novadiscovery Recent Development

 Table 120. Recursion Pharmaceuticals Company Details

 Table 121. Recursion Pharmaceuticals Business Overview

 Table 122. Recursion Pharmaceuticals In-Silico Drug Discovery Product

 Table 123. Recursion Pharmaceuticals Revenue in In-Silico Drug Discovery Business (US$ Million), 2021–2026

 Table 124. Recursion Pharmaceuticals Recent Development

 Table 125. insitro Company Details

 Table 126. insitro Business Overview

 Table 127. insitro In-Silico Drug Discovery Product

 Table 128. insitro Revenue in In-Silico Drug Discovery Business (US$ Million), 2021–2026

 Table 129. insitro Recent Development

 Table 130. Numerion Labs (formerly Atomwise) Company Details

 Table 131. Numerion Labs (formerly Atomwise) Business Overview

 Table 132. Numerion Labs (formerly Atomwise) In-Silico Drug Discovery Product

 Table 133. Numerion Labs (formerly Atomwise) Revenue in In-Silico Drug Discovery Business (US$ Million), 2021–2026

 Table 134. Numerion Labs (formerly Atomwise) Recent Development

 Table 135. BenevolentAI Company Details

 Table 136. BenevolentAI Business Overview

 Table 137. BenevolentAI In-Silico Drug Discovery Product

 Table 138. BenevolentAI Revenue in In-Silico Drug Discovery Business (US$ Million), 2021–2026

 Table 139. BenevolentAI Recent Development

 Table 140. XtalPi Company Details

 Table 141. XtalPi Business Overview

 Table 142. XtalPi In-Silico Drug Discovery Product

 Table 143. XtalPi Revenue in In-Silico Drug Discovery Business (US$ Million), 2021–2026

 Table 144. XtalPi Recent Development

 Table 145. Research Programs/Design for This Report

 Table 146. Key Data Information from Secondary Sources

 Table 147. Key Data Information from Primary Sources

 Table 148. Authors List of This Report

List of Figures

 Figure 1. In-Silico Drug Discovery Picture

 Figure 2. Global In-Silico Drug Discovery Market Size Comparison by Type (US$ Million), 2021–2032

 Figure 3. Global In-Silico Drug Discovery Market Share by Type: 2025 vs 2032

 Figure 4. Software as a Service (Cloud) Features

 Figure 5. Consultancy as a Service Features

 Figure 6. Software Features

 Figure 7. Global In-Silico Drug Discovery Market Size Comparison by Method Paradigm (US$ Million), 2021–2032

 Figure 8. Physics and Structure-based Features

 Figure 9. Data-driven Features

 Figure 10. Hybrid Features

 Figure 11. Global In-Silico Drug Discovery Market Size Comparison by Modality (US$ Million), 2021–2032

 Figure 12. Small Molecule-first Features

 Figure 13. Biologics/Antibody-focused Features

 Figure 14. Multi-modality Features

 Figure 15. Global In-Silico Drug Discovery Market Size by Application (US$ Million), 2021–2032

 Figure 16. Global In-Silico Drug Discovery Market Share by Application: 2025 vs 2032

 Figure 17. Contract Research Organization Case Studies

 Figure 18. Pharmaceutical Industry Case Studies

 Figure 19. Academic and Research Institutes Case Studies

 Figure 20. Others Case Studies

 Figure 21. In-Silico Drug Discovery Report Years Considered

 Figure 22. Global In-Silico Drug Discovery Market Size (US$ Million), Year-over-Year: 2021–2032

 Figure 23. Global In-Silico Drug Discovery Market Size, (US$ Million), 2021 vs 2025 vs 2032

 Figure 24. Global In-Silico Drug Discovery Market Share by Region: 2025 vs 2032

 Figure 25. Global In-Silico Drug Discovery Market Share by Players in 2025

 Figure 26. Global In-Silico Drug Discovery Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

 Figure 27. The Top 10 and 5 Players Market Share by In-Silico Drug Discovery Revenue in 2025

 Figure 28. North America In-Silico Drug Discovery Market Size YoY Growth (US$ Million), 2021–2032

 Figure 29. North America In-Silico Drug Discovery Market Share by Country (2021–2032)

 Figure 30. United States In-Silico Drug Discovery Market Size YoY Growth (US$ Million), 2021–2032

 Figure 31. Canada In-Silico Drug Discovery Market Size YoY Growth (US$ Million), 2021–2032

 Figure 32. Europe In-Silico Drug Discovery Market Size YoY Growth (US$ Million), 2021–2032

 Figure 33. Europe In-Silico Drug Discovery Market Share by Country (2021–2032)

 Figure 34. Germany In-Silico Drug Discovery Market Size YoY Growth (US$ Million), 2021–2032

 Figure 35. France In-Silico Drug Discovery Market Size YoY Growth (US$ Million), 2021–2032

 Figure 36. U.K. In-Silico Drug Discovery Market Size YoY Growth (US$ Million), 2021–2032

 Figure 37. Italy In-Silico Drug Discovery Market Size YoY Growth (US$ Million), 2021–2032

 Figure 38. Russia In-Silico Drug Discovery Market Size YoY Growth (US$ Million), 2021–2032

 Figure 39. Ireland In-Silico Drug Discovery Market Size YoY Growth (US$ Million), 2021–2032

 Figure 40. Asia-Pacific In-Silico Drug Discovery Market Size YoY Growth (US$ Million), 2021–2032

 Figure 41. Asia-Pacific In-Silico Drug Discovery Market Share by Region (2021–2032)

 Figure 42. China In-Silico Drug Discovery Market Size YoY Growth (US$ Million), 2021–2032

 Figure 43. Japan In-Silico Drug Discovery Market Size YoY Growth (US$ Million), 2021–2032

 Figure 44. South Korea In-Silico Drug Discovery Market Size YoY Growth (US$ Million), 2021–2032

 Figure 45. Southeast Asia In-Silico Drug Discovery Market Size YoY Growth (US$ Million), 2021–2032

 Figure 46. India In-Silico Drug Discovery Market Size YoY Growth (US$ Million), 2021–2032

 Figure 47. Australia & New Zealand In-Silico Drug Discovery Market Size YoY Growth (US$ Million), 2021–2032

 Figure 48. Latin America In-Silico Drug Discovery Market Size YoY Growth (US$ Million), 2021–2032

 Figure 49. Latin America In-Silico Drug Discovery Market Share by Country (2021–2032)

 Figure 50. Mexico In-Silico Drug Discovery Market Size YoY Growth (US$ Million), 2021–2032

 Figure 51. Brazil In-Silico Drug Discovery Market Size YoY Growth (US$ Million), 2021–2032

 Figure 52. Middle East & Africa In-Silico Drug Discovery Market Size YoY Growth (US$ Million), 2021–2032

 Figure 53. Middle East & Africa In-Silico Drug Discovery Market Share by Country (2021–2032)

 Figure 54. Israel In-Silico Drug Discovery Market Size YoY Growth (US$ Million), 2021–2032

 Figure 55. Saudi Arabia In-Silico Drug Discovery Market Size YoY Growth (US$ Million), 2021–2032

 Figure 56. UAE In-Silico Drug Discovery Market Size YoY Growth (US$ Million), 2021–2032

 Figure 57. Allucent (formerly Nuventra) Revenue Growth Rate in In-Silico Drug Discovery Business (2021–2026)

 Figure 58. Jubilant Biosys Revenue Growth Rate in In-Silico Drug Discovery Business (2021–2026)

 Figure 59. Shanghai ChemPartner Co., Ltd Revenue Growth Rate in In-Silico Drug Discovery Business (2021–2026)

 Figure 60. Shanghai Medicilon Inc. Revenue Growth Rate in In-Silico Drug Discovery Business (2021–2026)

 Figure 61. Pharmaron Revenue Growth Rate in In-Silico Drug Discovery Business (2021–2026)

 Figure 62. BioDuro-Sundia Revenue Growth Rate in In-Silico Drug Discovery Business (2021–2026)

 Figure 63. Syngene Revenue Growth Rate in In-Silico Drug Discovery Business (2021–2026)

 Figure 64. TCG Lifesciences Private Limited Revenue Growth Rate in In-Silico Drug Discovery Business (2021–2026)

 Figure 65. Viva Biotech (Shanghai) Ltd Revenue Growth Rate in In-Silico Drug Discovery Business (2021–2026)

 Figure 66. Profacgen Revenue Growth Rate in In-Silico Drug Discovery Business (2021–2026)

 Figure 67. Creative BioLabs Revenue Growth Rate in In-Silico Drug Discovery Business (2021–2026)

 Figure 68. Aitia (formerly GNS Healthcare) Revenue Growth Rate in In-Silico Drug Discovery Business (2021–2026)

 Figure 69. Novadiscovery Revenue Growth Rate in In-Silico Drug Discovery Business (2021–2026)

 Figure 70. Recursion Pharmaceuticals Revenue Growth Rate in In-Silico Drug Discovery Business (2021–2026)

 Figure 71. insitro Revenue Growth Rate in In-Silico Drug Discovery Business (2021–2026)

 Figure 72. Numerion Labs (formerly Atomwise) Revenue Growth Rate in In-Silico Drug Discovery Business (2021–2026)

 Figure 73. BenevolentAI Revenue Growth Rate in In-Silico Drug Discovery Business (2021–2026)

 Figure 74. XtalPi Revenue Growth Rate in In-Silico Drug Discovery Business (2021–2026)

 Figure 75. Bottom-up and Top-down Approaches for This Report

 Figure 76. Data Triangulation

 Figure 77. Key Executives Interviewed